Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryogenic silicification enables nongenetic functional continuity across mammalian cell generations.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Assessment of radionuclide levels, annual effective dose, and lifetime cancer risk from cultivated crop samples in Hainan Island, China.

Frontiers in public health·2026
Same author

Harnessing Silicene-to-Silicic Acid Conversion for Organelle-Specific Silica Deposition in Tumor Therapy.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Wind-power curve anomaly type recognition via image-topology-semantic multi-feature fusion and contrastive learning.

Scientific reports·2026
Same author

Rare variants of <i>GPSM2</i> associated with aneuploidy-mediated recurrent spontaneous abortion: mechanistic insights from siRNA knockdown modeling of hypothesized loss-of-function.

Frontiers in cell and developmental biology·2026
Same author

Impact of reduced <sup>18</sup>F-MK6240 PET/MR acquisition duration on image quality and tau pathology assessment in patients with cognitive impairment.

EJNMMI physics·2026

Related Experiment Video

Updated: Jul 16, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Nanomaterials Drive In Vivo CAR Immune Cells Engineering.

Meifen Luo1, Kai Liao1, Jinxi Chang2

  • 1Department of Minimally Invasive Interventional Radiology, School of Biomedical Engineering & The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, P. R. China.

Advanced Materials (Deerfield Beach, Fla.)
|July 15, 2026
PubMed
Summary

In vivo chimeric antigen receptor (CAR) engineering offers a simpler alternative to complex ex vivo cell manufacturing. This approach uses nanocarriers for direct genetic material delivery, overcoming limitations of current CAR therapies.

Keywords:
CAR immune cellscell therapyclinical translationin vivo cell engineeringnanocarriers

More Related Videos

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Chimeric antigen receptor (CAR) immune cell therapy is effective for tumors and autoimmune diseases.
  • Conventional ex vivo CAR manufacturing faces challenges like high cost and variability.
  • These limitations necessitate exploring alternative production methods.

Purpose of the Study:

  • To review the evolution of CAR therapy and limitations of ex vivo manufacturing.
  • To examine nanocarrier-based delivery platforms for in vivo CAR engineering.
  • To compare delivery efficiency, tropism, and expression kinetics of different in vivo strategies.

Main Methods:

  • Review of existing literature on CAR therapy and nanocarrier delivery systems.
  • Comparative analysis of in vivo delivery platforms based on efficiency, tropism, and expression kinetics.
  • Discussion of challenges and trade-offs in clinical translation.

Main Results:

  • In vivo CAR engineering via nanocarriers simplifies production compared to ex vivo methods.
  • Analysis highlights distinctions between transient and durable expression strategies.
  • Key challenges include immune activation, nanocarrier immunogenicity, and tumor microenvironment barriers.

Conclusions:

  • In vivo CAR engineering presents a promising alternative to ex vivo manufacturing.
  • Optimizing delivery precision, immune compatibility, and expression control is crucial for clinical translation.
  • Balancing therapeutic durability and biosafety is essential for advancing CAR therapies.